George Thomas

Associate Professor

  • 53214 Citations
  • 59 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where George Thomas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.



    Mori, M. (., Corless, C., Beer, T. (., McWeeney, S., Harrington, C. (., Bagby, G., Druker, B., Sexton, G., Hall, A., Henner, W., Samuels, M. H., Bakke, A., Hoatlin, M., Baetscher, M., Keller, T., Nagalla, S., Magun, B. E., Koop, D. R., Mauro, M. J., Blanke, C. D., Bakke, A., Baetscher, M., Koop, D., Spellman, P., David, L., Coussens, L., Streeter, P., Thomas, G., Mori, M. (., Mori, M. (., Harrington, C. (., Bergan, R. & Blanke, C.

    National Institutes of Health


    Project: Research project

  • Research Output

    • 53214 Citations
    • 59 h-Index
    • 90 Article
    • 6 Comment/debate
    • 6 Review article
    • 1 Letter

    A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

    Graff, J. N., Beer, T. M., Alumkal, J. J., Slottke, R. E., Redmond, W. L., Thomas, G. V., Thompson, R. F., Wood, M. A., Koguchi, Y., Chen, Y., Latour, E., Bergan, R. C., Drake, C. G. & Moran, A. E., Jul 2 2020, In : Journal for immunotherapy of cancer. 8, 2, e00642.

    Research output: Contribution to journalArticle

    Open Access
  • Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer

    Kwon, D. H., Zhang, L., Quigley, D. A., Foye, A., Chen, W. S., Wong, C. K., Feng, F. Y., Bailey, A., Huang, J., Stuart, J. M., Friedl, V., Weinstein, A. S., Beer, T. M., Alumkal, J., Rettig, M., Gleave, M., Lara, P. N., Thomas, G. V., Li, P., Lui, A. & 2 others, Small, E. J. & Aggarwal, R. R., 2020, (Accepted/In press) In : Urologic Oncology: Seminars and Original Investigations.

    Research output: Contribution to journalArticle

  • Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial

    Zhang, Z., Garzotto, M., Davis, E. W., Mori, M., Stoller, W. A., Farris, P. E., Wong, C. P., Beaver, L. M., Thomas, G. V., Williams, D. E., Dashwood, R. H., Hendrix, D. A., Ho, E. & Shannon, J., Jan 2 2020, In : Nutrition and Cancer. 72, 1, p. 74-87 14 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer(Figure presented.)

    Chen, W. S., Aggarwal, R., Zhang, L., Zhao, S. G., Thomas, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., Lloyd, P., Lu, E., Sun, D., Guan, X., Rettig, M., Gleave, M., Evans, C. P., Youngren, J., True, L., Lara, P. & 8 others, Kothari, V., Xia, Z., Chi, K. N., Reiter, R. E., Maher, C. A., Feng, F. Y., Small, E. J. & Alumkal, J. J., Nov 2019, In : European Urology. 76, 5, p. 562-571 10 p.

    Research output: Contribution to journalArticle

  • 18 Scopus citations

    MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

    Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., Thomas, G. V., Howard, L., De Hoedt, A. M., Stuart, J., Goldstein, T., Chi, K., Gleave, M. E., Graff, J. N., Beer, T. M., Drake, J. M., Evans, C. P. & 11 others, Aggarwal, R., Foye, A., Feng, F. Y., Small, E. J., Aronson, W. J., Freedland, S. J., Witte, O. N., Huang, J., Alumkal, J. J., Reiter, R. E. & Rettig, M. B., Dec 1 2019, In : Prostate Cancer and Prostatic Diseases. 22, 4, p. 531-538 8 p.

    Research output: Contribution to journalArticle

    Open Access
  • 9 Scopus citations